Mr Mrs Miss Ms Dr Other

Mr
Matthew
Johnson

Partner & Patent Attorney

Manchester Office Alderley Park Office

Chemistry

Telephone. +44(0) 161 247 4900
Mobile. +44(0) 738 487 7684
Email. mjohnson@hgf.com
UPC Representative
Our team of specialist European patent litigators, oppositions specialists and patent attorneys bring together an extensive depth of legal and technical knowledge and are qualified to represent you in the UPC.

Experience

Matthew has extensive experience relating to the pharmaceutical industry, having started his career in medicinal chemistry at GSK where he delivered small molecule development candidates for neurological indications, such as Alzheimer's Disease and neuropathic and inflammatory pain.

Matthew specializes in obtaining and defending rights relating to pharmaceutical subject matter including new chemical entities, crystal forms, synthetic processes, intermediates, formulations, combination products and medical uses. In addition to European patent drafting and prosecution, Matthew also manages the prosecution of patent portfolios worldwide, and also has experience of obtaining Supplementary Protection Certificates (SPCs) in many European countries.

He regularly provides advice to clients on EPO opposition and appeal strategy and has successfully defended and attacked patent rights covering various commercial products via the central opposition procedure at the EPO. Matthew also regularly assist his clients with due diligence activities associated with in-licencing, such as freedom-to-operate opinions.

Besides pharmaceuticals, Matthew regularly assists his clients obtain and defend patent rights in relation to agrochemicals, catalysis, polymers, cleantech and food science.

Qualifications

Patent Attorney

Chartered (UK)
Europe


MCHEM

Chemistry and Pharmacology

POSTGRADUATE DIPLOMA OR CERTIFICATE

Certificate in Intellectual Property Law

OTHER

Patent Attorney Litigator

Related News

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were …

Read article

The end of the Brexit overhang for trade marks: review, refile and revoke.

On the 31st December 2025, five years will have passed since the end of the Brexit transitional period on 31st December 2020. Why is this relevant? For UK cloned trade …

Read article
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details

Personal names as 'brands' in the world of fashion

Episode 1 Personal names as ‘brands’ in the world of fashion    

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.